Advertisement

11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients

  • M. PicchioEmail author
  • G. Berardi
  • A. Fodor
  • E. Busnardo
  • C. Crivellaro
  • G. Giovacchini
  • C. Fiorino
  • M. Kirienko
  • E. Incerti
  • C. Messa
  • L. Gianolli
  • N. Di Muzio
Original Article

Abstract

Purpose

To evaluate, in prostate cancer (PCa) patients the potential of 11C-choline PET/CT as a guide to helical tomotherapy (HTT) of lymph-node (LN) relapses with simultaneous integrated boost (SIB). The efficacy and feasibility of HTT in terms of acute toxicity were assessed.

Methods

We enrolled 83 PCa patients (mean age 68 years, range 51 – 82 years) with biochemical recurrence after radical primary treatment (mean serum PSA 7.61 ng/ml, range 0.37 – 187.00 ng/ml; PSA0) who showed pathological findings on 11C-choline PET/CT only at the LN site. 11C-Choline PET/CT was performed for restaging and then for radiation treatment planning (PET/CT0). Of the 83 patients, 8 experienced further LN relapse, of whom 5 were retreated once and 3 were retreated twice (total 94 radiotherapy treatments). All pelvic and/or abdominal LNs positive on PET/CT0 were treated with high doses using SIB. Doses were in the range 36 – 74 Gy administered in 28 fractions. After the end of HTT (mean 83 days, range 16 – 365 days), serum PSA was measured in all patients (PSA1) and compared with PSA0 to evaluate early biochemical response. In 47 patients PET/CT was repeated (PET/CT1) to assess metabolic responses at the treated areas. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) were used to assess acute toxicity.

Results

PET/CT0 revealed pathological LNs in the pelvis in 49 patients, pathological LNs in the abdomen in 15 patients pathological LNs in both the pelvis and abdomen in 18 patients, and pathological LNs in the pelvis or abdomen and other sites in 12 patients. All these sites were treated with HTT. With respect to PSA0, PSA1 (mean 6.28 ng/ml, range 0.00 – 220.46 ng/ml) showed a complete biochemical response after 66 of the 94 HTT treatments, a partial response after 12 treatments, stable disease after 1 treatment and progression of disease after 15 treatments. Of the 47 patients receiving PET/CT1, 20 showed a complete metabolic response at the treated area, 22 a partial metabolic response, 3 progression of disease and 2 stable disease. HTT with SIB was well tolerated in all patients. Grade 3 acute toxicity in the genitourinary tract was observed in two patients.

Conclusion

11C-Choline PET/CT is a valuable tool for planning and monitoring HTT in LN relapse after primary treatment. High-dose hypofractionated 11C-choline PET/CT-guided HTT with SIB is well tolerated and is associated with a high early biochemical response rate.

Keywords

Choline PET/CT Prostate cancer Lymph-node relapse HTT RT SIB 

Notes

Conflicts of interest

None.

References

  1. 1.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170:1872–6. doi: 10.1097/01.ju.0000091876.13656.2e.PubMedCrossRefGoogle Scholar
  2. 2.
    Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004;100:1283–92. doi: 10.1002/cncr.20093.PubMedCrossRefGoogle Scholar
  3. 3.
    Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211–6. doi: 10.1038/sj.pcan.4500732.PubMedCrossRefGoogle Scholar
  4. 4.
    Gronau E, Goppelt M, Harzmann R, Weckermann D. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. Onkologie. 2005;28:361–6. doi: 10.1159/000085661.PubMedCrossRefGoogle Scholar
  5. 5.
    Iversen P, Roder MA. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther. 2008;8:361–9. doi: 10.1586/14737140.8.3.361.PubMedCrossRefGoogle Scholar
  6. 6.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, et al. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol. 2013;189:105–10. doi: 10.1016/j.juro.2012.09.001.PubMedCrossRefGoogle Scholar
  8. 8.
    Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43. doi: 10.1016/j.eururo.2011.07.060.PubMedCrossRefGoogle Scholar
  9. 9.
    Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–95. doi: 10.1016/j.crad.2007.05.022.PubMedCrossRefGoogle Scholar
  10. 10.
    Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38.e9–16. doi: 10.1016/j.urolonc.2013.03.006.CrossRefGoogle Scholar
  11. 11.
    Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106–17. doi: 10.1016/j.eururo.2013.04.019.PubMedCrossRefGoogle Scholar
  12. 12.
    Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60. doi: 10.1016/j.eururo.2010.09.004.PubMedCrossRefGoogle Scholar
  13. 13.
    Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63:792–6. doi: 10.1016/j.eururo.2012.08.003.PubMedCrossRefGoogle Scholar
  14. 14.
    Suardi N, Briganti A, Salonia A, Rigatti P. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. Curr Opin Urol. 2011;21:237–40. doi: 10.1097/MOU.0b013e328344e4c4.PubMedCrossRefGoogle Scholar
  15. 15.
    Winter A, Uphoff J, Henke RP, Wawroschek F. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int. 2010;84:418–23. doi: 10.1159/000296298.PubMedCrossRefGoogle Scholar
  16. 16.
    Martorana G, Schiavina R, Franceschelli A. Should we perform imaging-guided lymph node dissection in patients with lymphatic recurrence of prostate cancer after radical prostatectomy? Eur Urol. 2009;55:1302–4. doi: 10.1016/j.eururo.2008.08.011.PubMedCrossRefGoogle Scholar
  17. 17.
    Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446–51. doi: 10.1111/j.1464-410X.2008.07592.x.PubMedCrossRefGoogle Scholar
  18. 18.
    Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14–7. doi: 10.1016/j.radonc.2009.04.001.PubMedCrossRefGoogle Scholar
  19. 19.
    Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97. doi: 10.1016/j.ijrobp.2010.11.031.PubMedCrossRefGoogle Scholar
  20. 20.
    Jereczek-Fossa BA, Kowalczyk A, D’Onofrio A, Catalano G, Garibaldi C, Boboc G, et al. Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients. Strahlenther Onkol. 2008;184:36–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Alongi F, Schipani S, Gajate AM, Rosso A, Cozzarini C, Fiorino C, et al. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori. 2010;96:613–7.PubMedGoogle Scholar
  22. 22.
    Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96:347–50. doi: 10.1016/j.radonc.2010.07.016.PubMedCrossRefGoogle Scholar
  23. 23.
    Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14. doi: 10.1186/1748-717X-7-14.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193–200. doi: 10.1016/j.radonc.2011.05.005.PubMedCrossRefGoogle Scholar
  25. 25.
    Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44. doi: 10.1186/1748-717X-6-44.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.PubMedGoogle Scholar
  27. 27.
    Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, et al. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol. 2011;187:479–84. doi: 10.1007/s00066-011-2249-z.PubMedCrossRefGoogle Scholar
  28. 28.
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.PubMedCrossRefGoogle Scholar
  29. 29.
    Bettinardi V, Danna M, Savi A, Lecchi M, Castiglioni I, Gilardi MC, et al. Performance evaluation of the new whole-body PET/CT scanner: Discovery ST. Eur J Nucl Med Mol Imaging. 2004;31:867–81. doi: 10.1007/s00259-003-1444-2.PubMedCrossRefGoogle Scholar
  30. 30.
    Bettinardi V, Mancosu P, Danna M, Giovacchini G, Landoni C, Picchio M, et al. Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study. Q J Nucl Med Mol Imaging. 2007;51:214–23.PubMedGoogle Scholar
  31. 31.
    Messa C, Bettinardi V, Picchio M, Pelosi E, Landoni C, Gianolli L, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging. 2004;48:66–75.PubMedGoogle Scholar
  32. 32.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2009;37:301–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Fiorino C, Alongi F, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, et al. Physics aspects of prostate tomotherapy: planning optimization and image-guidance issues. Acta Oncol. 2008;47:1309–16. doi: 10.1080/02841860802266755.PubMedCrossRefGoogle Scholar
  34. 34.
    Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, et al. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:392–8. doi: 10.1016/j.ijrobp.2008.08.038.PubMedCrossRefGoogle Scholar
  35. 35.
    Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol. 2007;84:164–70. doi: 10.1016/j.radonc.2007.07.013.PubMedCrossRefGoogle Scholar
  36. 36.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6. doi: 10.1016/0360-3016(95)00060-C.PubMedCrossRefGoogle Scholar
  37. 37.
    McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, et al. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013;85:e39–46. doi: 10.1016/j.ijrobp.2012.08.036.PubMedCrossRefGoogle Scholar
  38. 38.
    Yossepowitch O, Bianco Jr FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007;51:940–7; discussion 947–8. doi: 10.1016/j.eururo.2006.10.045.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–9. doi: 10.1111/j.1464-410X.2011.10422.x.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Sironi S, Buda A, Picchio M, Perego P, Moreni R, Pellegrino A, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology. 2006;238:272–9. doi: 10.1148/radiol.2381041799.PubMedCrossRefGoogle Scholar
  41. 41.
    Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. doi: 10.1016/j.eururo.2007.03.032.PubMedCrossRefGoogle Scholar
  42. 42.
    Suardi NG, Briganti A, Picchio M, Gallina A, Messa C, Gianolli L, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: validation by open pelvic-retroperitoneal lymphadenectomy. J Urol. 2009;181:829.CrossRefGoogle Scholar
  43. 43.
    Picchio M, Alongi F, Giovacchini G, Berardi G, Busnardo E, Crivellaro C, et al. 11C-Choline PET/CT image-guided tomotherapy treatment of lymph nodal relapse in prostate cancer patients. J Nucl Med. 2010;51:1274.Google Scholar
  44. 44.
    Picchio M, Alongi F, Giovacchini G, Di Rosa E, Cozzarini C, Landoni C, et al. 11C-Choline PET/CT image-guided radiotherapeutic treatment of lymph nodal recurrence in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2008;35:388.Google Scholar
  45. 45.
    Pantaleo MA, Nannini M, Lopci E, Castellucci P, Maleddu A, Lodi F, et al. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. Int J Oncol. 2008;33:443–52.PubMedGoogle Scholar
  46. 46.
    Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74. doi: 10.1016/j.ijrobp.2006.04.029.PubMedCrossRefGoogle Scholar
  47. 47.
    Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75:29–35. doi: 10.1016/j.ijrobp.2008.10.086.PubMedCrossRefGoogle Scholar
  48. 48.
    Van Poppel H. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy? Eur Urol. 2009;55:1012–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104–11. doi: 10.1016/S0140-6736(11)61095-7.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • M. Picchio
    • 1
    Email author
  • G. Berardi
    • 2
  • A. Fodor
    • 2
  • E. Busnardo
    • 1
  • C. Crivellaro
    • 3
  • G. Giovacchini
    • 1
  • C. Fiorino
    • 4
  • M. Kirienko
    • 5
  • E. Incerti
    • 1
  • C. Messa
    • 5
    • 6
  • L. Gianolli
    • 1
  • N. Di Muzio
    • 2
  1. 1.Nuclear Medicine UnitSan Raffaele Scientific InstituteMilanItaly
  2. 2.Radiotherapy UnitSan Raffaele Scientific InstituteMilanItaly
  3. 3.Nuclear Medicine UnitSan Gerardo HospitalMonzaItaly
  4. 4.Medical Physics UnitSan Raffaele Scientific InstituteMilanItaly
  5. 5.University of Milano-BicoccaMilanItaly
  6. 6.Institute for Bioimaging and Molecular PhysiologyNational Research Council (IBFM-CNR)MilanItaly

Personalised recommendations